| Symbol | ICLR |
|---|---|
| Name | ICON PLC |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Commercial Physical & Biological Resarch |
| Address | SOUTH COUNTY BUSINESS PARK,LEOPARDSTOWN, DUBLIN, D18 X5R3, Ireland |
| Telephone | +353 12912000 |
| Fax | — |
| — | |
| Website | https://www.iconplc.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001060955 |
| Description | Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland. Additional info from NASDAQ: |
2026-05-15 17:17
New Form SCHEDULE 13G - ICON PLC <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0000813917-26-000033 <b>Size:</b> 8 KB
Read more
2026-05-13 12:00
ICON expands US early phase research capabilities with new clinic and outpatient centres
Read more
2026-05-06 17:04
New Form SCHEDULE 13G - ICON PLC <b>Filed:</b> 2026-05-06 <b>AccNo:</b> 0000914208-26-000127 <b>Size:</b> 13 KB
Read more
2026-05-01 17:15
New Form NT 20-F - ICON PLC <b>Filed:</b> 2026-05-01 <b>AccNo:</b> 0001628280-26-029338 <b>Size:</b> 40 KB
Read more
2026-04-29 11:00
ICON Provides Update on Audit Committee Investigation and Timing of Fourth Quarter and Full Year 2025 Financial Results
Read more
2026-03-24 12:00
ICON and Advarra Introduce New ‘Research-Ready,’ Connected Site Network Model
Read more
2026-03-18 17:36
New Form 3 - ICON PLC <b>Filed:</b> 2026-03-18 <b>AccNo:</b> 0001628280-26-019445 <b>Size:</b> 26 KB
Read more
2026-03-18 17:20
New Form 3 - ICON PLC <b>Filed:</b> 2026-03-18 <b>AccNo:</b> 0001628280-26-019422 <b>Size:</b> 18 KB
Read more
2026-03-18 17:14
New Form 3 - ICON PLC <b>Filed:</b> 2026-03-18 <b>AccNo:</b> 0001628280-26-019412 <b>Size:</b> 19 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07514338 | Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patie… | Phase2 | Mitochondrial Diseases | Not_Yet_Recruiting | 2026-06-09 | 2029-03-31 | ClinicalTrials.gov |
| NCT07430306 | A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immun… | Phase3 | Systemic Lupus Erythematosus | Recruiting | 2026-04-13 | 2029-01-26 | ClinicalTrials.gov |
| NCT07338214 | Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product… | Phase1 | Obesity & Overweight | Completed | 2025-12-17 | 2026-03-31 | ClinicalTrials.gov |
| NCT07205666 | The Eplontersen Pregnancy and Lactation Outcomes Study | — | Transthyretin Amyloidosis | Recruiting | 2025-11-30 | 2035-12-30 | ClinicalTrials.gov |
| NCT07199569 | Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production … | Phase2 | Monkeypox (Mpox) | Active_Not_Recruiting | 2025-10-27 | 2026-11-30 | ClinicalTrials.gov |
| NCT07059000 | A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults Wit… | Phase3 | Chronic Primary Immune Thrombocytopenia (ITP) | Recruiting | 2025-08-13 | 2026-08-01 | ClinicalTrials.gov |
| NCT07126262 | A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 … | Phase2 | Hypochondroplasia | Recruiting | 2025-07-30 | 2028-06-30 | ClinicalTrials.gov |
| NCT06328608 | A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Chil… | Phase2 | Fabry Disease | Recruiting | 2025-07-29 | 2031-04-01 | ClinicalTrials.gov |
| NCT06941025 | Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry As… | — | Fabry Disease | Recruiting | 2025-05-23 | 2034-12-01 | ClinicalTrials.gov |
| NCT07076030 | Pharmacokinetics of Petrelintide Following Administration to Participants With … | Phase1 | Renal Impairment | Completed | 2025-04-15 | 2025-11-25 | ClinicalTrials.gov |
| NCT06716606 | A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults… | Phase3 | Connective Tissue Diseases | Recruiting | 2024-12-12 | 2029-12-27 | ClinicalTrials.gov |
| NCT06507566 | Evaluating Technologies for Point-of-Care Blood Collections by Patients | Na | Healthy | Completed | 2024-10-29 | 2025-04-04 | ClinicalTrials.gov |
| NCT06560151 | Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vacci… | Phase2 | Influenza | Completed | 2024-08-21 | 2025-06-11 | ClinicalTrials.gov |
| NCT06465810 | Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis | — | Transthyretin Amyloidosis | Recruiting | 2024-06-25 | 2031-12-29 | ClinicalTrials.gov |
| NCT06274853 | GS-441524 for COVID-19 SAD, FE, and MAD Study in Healthy Subjects | Phase1 | COVID-19 | Withdrawn | 2024-06-15 | 2024-12-01 | ClinicalTrials.gov |
| NCT06476405 | Room Air Levels of Harmful and Potentially Harmful Constituents After Heated To… | — | Tobacco Smoking | Completed | 2024-06-10 | 2025-03-11 | ClinicalTrials.gov |
| NCT06385509 | A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JA… | Phase4 | Hypogonadism | Active_Not_Recruiting | 2024-05-10 | 2026-03-01 | ClinicalTrials.gov |
| NCT06401213 | A First-in-Human Safety Trial of MTX-463 | Phase1 | Healthy | Completed | 2024-04-15 | 2024-11-15 | ClinicalTrials.gov |
| NCT06017609 | Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Fa… | Phase2 | Chronic Heart Failure | Active_Not_Recruiting | 2023-12-20 | 2026-12-01 | ClinicalTrials.gov |
| NCT05997264 | Anthrax AV7909 Boost Evaluation Study | Phase2 | Anthrax | Active_Not_Recruiting | 2023-12-05 | 2026-08-01 | ClinicalTrials.gov |
| NCT05693909 | A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or … | Phase2 | Beta Thalassemia Major Anemia | Recruiting | 2023-09-04 | 2028-05-01 | ClinicalTrials.gov |
| NCT05361486 | Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD T… | — | Malaria, Vivax | Completed | 2023-08-28 | 2024-12-31 | ClinicalTrials.gov |
| NCT06956495 | Efficacy and Tolerability of Tasipimidine in Sleepless Patients | Phase2 | Insomnia | Completed | 2023-08-20 | 2025-09-24 | ClinicalTrials.gov |
| NCT05710692 | Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patie… | Phase2 | Fabry Disease | Recruiting | 2023-08-01 | 2029-08-01 | ClinicalTrials.gov |
| NCT05979207 | Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Inf… | Phase1 | Infections | Completed | 2023-08-01 | 2023-10-30 | ClinicalTrials.gov |
| NCT05910450 | A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatme… | Phase3 | Alopecia, Androgenetic | Active_Not_Recruiting | 2023-06-21 | 2026-06-01 | ClinicalTrials.gov |
| NCT05871541 | A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vacci… | Phase1 | Herpes Zoster (HZ) | Completed | 2023-05-26 | 2024-03-25 | ClinicalTrials.gov |
| NCT06252753 | Observational Study Protocol: LIVER-R | — | Hepatobiliary Cancers | Recruiting | 2023-03-16 | 2030-12-30 | ClinicalTrials.gov |
| NCT05743335 | A Phase 1 Study to Assess the Safety and Immunogenicity of JCXH-221, an MRNA-ba… | Phase1 | COVID-19 | Completed | 2023-03-07 | 2023-12-01 | ClinicalTrials.gov |
| NCT05127915 | US Pivotal Clinical Study of the Adient Absorbable Filter for the Prevention of… | Na | Pulmonary Embolism | Active_Not_Recruiting | 2023-01-27 | 2026-12-31 | ClinicalTrials.gov |
| NCT05723692 | A First-In-Human SAD and MAD Study to Evaluate the Safety, Tolerability, PK and… | Phase1 | Healthy Volunteers | Completed | 2023-01-17 | 2023-10-27 | ClinicalTrials.gov |
| NCT05721001 | French Registry Conducted on E-vita OPEN NEO | — | Vascular Aneurysm | Active_Not_Recruiting | 2023-01-11 | 2027-08-31 | ClinicalTrials.gov |
| NCT05529472 | Safety and Effectiveness Evaluation of Peripheral Orbital Atherectomy | Na | Peripheral Artery Disease | Completed | 2023-01-10 | 2024-10-10 | ClinicalTrials.gov |
| NCT05322590 | BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma | Phase1 | Metastatic Colorectal Carcinoma | Active_Not_Recruiting | 2023-01-09 | 2029-04-01 | ClinicalTrials.gov |
| NCT05171946 | Phase-I Study to Evaluate the Safety and Immunogenicity of a Prophylactic pDNA … | Phase1 | Safety | Unknown | 2022-11-20 | 2023-07-01 | ClinicalTrials.gov |
| NCT05599308 | Evaluation of Blood Pressure Monitor With AFib Screening Feature | Na | Atrial Fibrillation | Completed | 2022-09-06 | 2023-04-11 | ClinicalTrials.gov |
| NCT06125717 | Phase 1 Evaluation of H1 Influenza Vaccine Delivered by MIMIX MAP | Phase1 | Influenza | Completed | 2022-07-02 | 2023-03-13 | ClinicalTrials.gov |
| NCT05429840 | Safety & PK of Single Doses of MT1980 | Phase1 | Neuroinflammatory Response | Completed | 2022-06-01 | 2022-10-04 | ClinicalTrials.gov |
| NCT05334108 | Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmaco… | Phase1 | Drug Interaction | Completed | 2022-04-26 | 2022-08-26 | ClinicalTrials.gov |
| NCT05388474 | A Prospective and Retrospective Observational Study of Multidrug-Resistant Pati… | — | HIV Infections | Active_Not_Recruiting | 2022-03-22 | 2026-06-01 | ClinicalTrials.gov |
| NCT05331976 | A Clinical Evaluation of Proof Diagnostics Test System Including the Proof Diag… | — | COVID-19 | Completed | 2022-02-09 | 2022-03-21 | ClinicalTrials.gov |
| NCT04985825 | Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma | Phase2 | Cutaneous Squamous Cell Carcinoma | Withdrawn | 2021-12-16 | 2022-08-17 | ClinicalTrials.gov |
| NCT04646603 | MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients | Phase2 | COVID-19 | Unknown | 2021-12-01 | 2022-07-01 | ClinicalTrials.gov |
| NCT04752358 | ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogas… | Phase2 | Esophageal Cancer | Terminated | 2021-09-15 | 2023-12-15 | ClinicalTrials.gov |
| NCT04844866 | Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients | Phase2 | Diffuse Large B-cell Lymphoma | Recruiting | 2021-08-18 | 2031-09-30 | ClinicalTrials.gov |
| NCT05107258 | A Clinical Evaluation of Pine Trees Health Test System Including the Pine Trees… | — | SARS (Severe Acute Respiratory Syndrome) | Completed | 2021-08-17 | 2021-09-16 | ClinicalTrials.gov |
| NCT04622007 | Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC … | Phase2 | Non-small Cell Lung Cancer | Active_Not_Recruiting | 2021-06-02 | 2024-12-09 | ClinicalTrials.gov |
| NCT04883333 | A Single and Multiple Ascending-dose Trial of LEO 153339 in Healthy Adults | Phase1 | Healthy | Completed | 2021-05-17 | 2022-07-18 | ClinicalTrials.gov |
| NCT04796935 | A Study to Test Performance of Needle Placements for Neuraxial Procedures Using… | Na | Central Nervous System Infections | Completed | 2021-04-04 | 2021-11-24 | ClinicalTrials.gov |
| NCT05312567 | FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms | Phase2 | Vasomotor Symptoms | Completed | 2021-03-24 | 2023-07-31 | ClinicalTrials.gov |
| NCT04761198 | A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Me… | Phase1 | Solid Tumor, Adult | Completed | 2021-03-23 | 2023-10-30 | ClinicalTrials.gov |
| NCT04620239 | ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHT… | Phase3 | Transitional Cell Cancer of Renal Pelvis and Ureter | Recruiting | 2021-03-22 | 2029-01-25 | ClinicalTrials.gov |
| NCT04432389 | Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB… | Phase2 | Tibial Fracture | Unknown | 2021-01-08 | 2024-03-31 | ClinicalTrials.gov |
| NCT04723602 | Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg … | Phase1 | Ebola Virus Disease | Completed | 2021-01-06 | 2021-12-14 | ClinicalTrials.gov |
| NCT04393779 | Observational Registry on the HARPOON Device | Na | Severe Degenerative Mitral Regurgitation Due to Mid-segment Posterior Leaflet Prolapse | Terminated | 2020-10-02 | 2022-11-17 | ClinicalTrials.gov |
| NCT04209543 | Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmeno… | Phase3 | Vasomotor Symptoms | Completed | 2019-12-30 | 2024-02-08 | ClinicalTrials.gov |
| NCT03744910 | Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in… | Phase3 | Antibody-mediated Rejection | Terminated | 2019-10-14 | 2024-04-08 | ClinicalTrials.gov |
| NCT04094363 | CSD190202: Study to Assess Elements of Abuse Liability for Two Electronic Nicot… | Na | Smoking | Completed | 2019-10-03 | 2019-11-26 | ClinicalTrials.gov |
| NCT04125810 | A Study to Assess the Safety and Efficacy of Probiotic to Modulate Psychologica… | Phase2 | Stress, Psychological | Completed | 2019-09-02 | 2020-02-07 | ClinicalTrials.gov |
| NCT04029363 | Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in… | Na | Mitral Regurgitation | Recruiting | 2019-05-28 | 2031-12-15 | ClinicalTrials.gov |
| NCT03870945 | Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1) | Phase1 | B-cell Non Hodgkin Lymphoma | Completed | 2019-02-25 | 2024-05-28 | ClinicalTrials.gov |
| NCT04773015 | A Study to Evaluate the Effectiveness of VIZAMYL™ Reader Training Programme in … | — | Cognitive Impairment | Completed | 2018-12-11 | 2021-12-07 | ClinicalTrials.gov |
| NCT03688776 | CSD1805: Study to Assess Nicotine Uptake and Product Use Behavior in Moist Snuf… | Na | Tobacco Use | Completed | 2018-10-19 | 2018-12-02 | ClinicalTrials.gov |
| NCT03806179 | Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL | Phase1 | Non Hodgkin Lymphoma | Completed | 2018-10-04 | 2022-08-08 | ClinicalTrials.gov |
| NCT03680105 | A Safety and Tolerability Study of RJX Drug Product in Healthy Participants | Phase1 | Critical Limb Ischemia | Completed | 2018-08-24 | 2019-01-15 | ClinicalTrials.gov |
| NCT03102606 | Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel … | Phase3 | Chemotherapy-induced Neutropenia | Completed | 2018-05-29 | 2021-02-08 | ClinicalTrials.gov |
| NCT03444324 | Adjusted Fibrinogen Replacement Strategy | Phase3 | Bleeding Disorder | Completed | 2018-04-03 | 2023-11-21 | ClinicalTrials.gov |
| NCT03758534 | Natural History of GACI With or Without ARHR2 or PXE | — | Generalized Arterial Calcification in Infancy | Unknown | 2018-03-15 | 2019-12-31 | ClinicalTrials.gov |
| NCT03195387 | Chemoprotective Activity of MMV390048 in PfSPZ Challenge Model | Phase1 | Malaria,Falciparum | Withdrawn | 2018-01-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT03416907 | Informed Consent Formats by Information Preference and Priority | Na | Consent Forms | Completed | 2017-11-27 | 2017-12-31 | ClinicalTrials.gov |
| NCT03153007 | Study of Subjects With Diabetic Foot Ulcer (DFU) | — | Diabetic Foot | Completed | 2017-08-11 | 2017-12-06 | ClinicalTrials.gov |
| NCT03170063 | FoxBioNet Pilot Project: SAVE (Synuclein Assay Validation Effort) | — | Parkinson Disease | Completed | 2017-08-08 | 2018-03-12 | ClinicalTrials.gov |
| NCT02974881 | HighLife™ Transcatheter Mitral Valve Replacement System Study | Na | Mitral Valve Regurgitation | Completed | 2017-07-20 | 2024-01-16 | ClinicalTrials.gov |
| NCT03046069 | FF/UMEC/VI Inhaler: Qualitative Analysis and Subject Preference Survey | — | Pulmonary Disease, Chronic Obstructive | Completed | 2017-02-20 | 2018-02-23 | ClinicalTrials.gov |
| NCT03060733 | Helicobacter Pylori Sample Collection Protocol Post Therapy Subjects | — | Helicobacter Pylori Infection | Completed | 2017-02-14 | 2018-05-14 | ClinicalTrials.gov |
| NCT03060746 | Helicobacter Pylori Sample Collection Protocol Pre Therapy Subjects | — | Helicobacter Pylori Infection | Completed | 2017-02-14 | 2018-05-03 | ClinicalTrials.gov |
| NCT02976753 | Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta C… | — | Hemophilia A | Completed | 2016-12-01 | 2021-11-03 | ClinicalTrials.gov |
| NCT02794168 | Efficacy of VAS203 (Ronopterin) in Patients With Moderate and Severe Traumatic … | Phase3 | Traumatic Brain Injury | Completed | 2016-06-01 | 2020-06-30 | ClinicalTrials.gov |
| NCT04017325 | European Randomised Study of TOOKAD® Soluble for Prostate Cancer vs Active Surv… | — | Cancer of the Prostate | Completed | 2016-03-17 | 2020-06-03 | ClinicalTrials.gov |
| NCT02656329 | International Study to Determine if AdreView Heart Function Scan Can be Used to… | Phase3 | Heart Failure | Terminated | 2015-12-30 | 2018-05-04 | ClinicalTrials.gov |
| NCT02547623 | Study to Evaluate the Safety for the Treatment of Inflammation Associated With … | Phase3 | Cataract | Completed | 2015-11-06 | 2016-08-16 | ClinicalTrials.gov |
| NCT02556177 | Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2 | Na | Concussion | Completed | 2015-11-01 | 2018-01-31 | ClinicalTrials.gov |
| NCT02596854 | Comparative Study of Conventional 1.5 and 3.0T MR Images With Synthetically Rec… | Na | Clinical Indication for Brain MRI | Completed | 2015-11-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02802059 | E. Coli Nissle 1917 - Suspension for Infection Prophylaxis | Phase3 | Infections | Completed | 2015-10-07 | 2020-10-12 | ClinicalTrials.gov |
| NCT02769780 | A Web-based Observational Study of Patient-reported Outcomes in Adults With Nar… | — | Narcolepsy | Completed | 2015-07-08 | 2021-08-09 | ClinicalTrials.gov |
| NCT02485431 | Food Effect and Bioavailability of Deflazacort Formulations in Healthy Voluntee… | Phase1 | Healthy Volunteers | Completed | 2015-06-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02518932 | The Effect of VTC-G15 (a Pentapeptide Cleavage Product og GLP-1) on Whole Body … | Phase1 | Insulin Resistance | Unknown | 2015-03-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT02351635 | BÜHLMANN fCAL™ ELISA - Aid in Differentiation of IBD From IBS | — | Inflammatory Bowel Disease | Completed | 2015-01-01 | 2018-04-01 | ClinicalTrials.gov |
| NCT02210221 | CENTER-TBI: Collaborative European NeuroTrauma Effectiveness Research in TBI | — | Traumatic Brain Injury | Completed | 2014-12-19 | 2021-03-31 | ClinicalTrials.gov |
| NCT02489682 | Clinical Informed Consent Format Evaluation | Na | Consent Forms | Completed | 2014-12-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02232425 | IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Report… | Phase2 | Premature Ejaculation | Completed | 2014-09-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02294877 | A Multicenter, Multinational, Observational Morquio A Registry Study (MARS) | — | Mucopolysaccharidosis IV Type A | Completed | 2014-09-01 | 2024-02-21 | ClinicalTrials.gov |
| NCT02065336 | A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface … | Phase2 | Hepatitis B, Chronic | Terminated | 2014-03-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT01850004 | Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With … | Phase2 | Chronic Phase Chronic Myeloid Leukemia | Completed | 2014-01-22 | 2021-10-08 | ClinicalTrials.gov |
| NCT02006888 | The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associat… | Phase3 | Inflammation | Completed | 2014-01-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01986426 | LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Com… | Phase1 | Cancer | Completed | 2013-11-01 | 2018-08-31 | ClinicalTrials.gov |
| NCT02047344 | Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC | Phase2 | Non-small Cell Lung Cancer Stage IV | Completed | 2013-10-01 | 2018-12-07 | ClinicalTrials.gov |
| NCT01838499 | Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects Wit… | Phase2 | Hidradenitis Suppurativa | Terminated | 2013-05-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT02065882 | Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibri… | Phase3 | Congenital Afibrinogenemia | Completed | 2013-03-01 | 2020-11-18 | ClinicalTrials.gov |
| NCT01796171 | A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma | Phase1 | Non-Hodgkin Lymphoma | Completed | 2012-12-01 | 2022-10-27 | ClinicalTrials.gov |
| NCT01593254 | Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) … | Phase2 | Chronic Phase Chronic Myeloid Leukemia | Completed | 2012-09-12 | 2022-04-12 | ClinicalTrials.gov |
| NCT01606735 | Efficacy and Safety of IBI-10090 in Ocular Surgery Patients | Phase2 | Inflammation Associated With Cataract Surgery | Completed | 2012-04-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01572909 | Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in … | Phase2 | Reperfusion Injury | Completed | 2012-04-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01453608 | A Study to Compare the Use of Ferric Carboxymaltose With Placebo in Patients Wi… | Phase4 | Iron Deficiency | Completed | 2011-10-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01421966 | Evaluation of CureXcell® in Treating Lower Extremity Chronic Ulcers in Adults W… | Phase3 | Lower Extremity Chronic Ulcers in Diabetics | Completed | 2011-08-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01350362 | Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzhe… | Phase2 | Alzheimer's Disease | Completed | 2011-04-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01336530 | Tepilta® Versus Oxetacaine, Antacids and Placebo | Phase3 | Radiation-induced Oesophagitis | Terminated | 2011-04-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT01244750 | Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world… | — | Chronic Myeloid Leukemia | Completed | 2010-12-02 | 2020-01-08 | ClinicalTrials.gov |
| NCT01809912 | Safety Study of MG1102 in Patients With Solid Tumors | Phase1 | Solid Tumors | Terminated | 2010-11-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01214174 | Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients | Phase2 | Ocular Inflammation | Terminated | 2010-10-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01175395 | 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Ag… | Phase1 | Age-Related Macular Degeneration | Completed | 2010-09-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01149720 | Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation Wit… | Phase1 | Solid Tumors | Completed | 2010-07-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT01128959 | Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adu… | Phase3 | Epilepsy | Completed | 2010-06-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01048593 | Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery | Phase2 | Inflammatory Reaction Due to Ocular Lens Prosthesis | Terminated | 2010-01-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00994318 | Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia… | Phase3 | Iron Deficiency Anaemia | Completed | 2009-12-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT00878878 | Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pul… | Phase4 | Pulmonary Hypertension | Completed | 2009-03-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00800501 | A Safety and Tolerability Study of Intracerebroventricular Administration of sN… | Phase1 | Amyotrophic Lateral Sclerosis | Completed | 2008-12-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT00409539 | SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (… | Phase2 | Overactive Bladder Syndrome (OABS) | Completed | 2006-12-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00430326 | Juvista (Avotermin) in Scars Following Varicose Vein Removal | Phase2 | Varicose Veins | Completed | 2006-11-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00358566 | GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in … | Phase3 | Advanced Unresectable Pancreatic Cancer | Terminated | 2006-06-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00179621 | Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31]… | Phase3 | Myelodysplastic Syndromes | Completed | 2005-07-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00221026 | Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the T… | Phase2 | Crohn's Disease | Completed | 2004-12-01 | 2006-06-01 | ClinicalTrials.gov |
Total clinical trials: 122
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| IBI-10090 | Other | Phase PHASE2 | Ocular Inflammation | TERMINATED | NCT01214174 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | Drug | Preclinical | Transthyretin Amyloidosis | RECRUITING | NCT06465810 |
| Anifrolumab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | RECRUITING | NCT07430306 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | Drug | Preclinical | Transthyretin Amyloidosis | RECRUITING | NCT06465810 |
| Anifrolumab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | RECRUITING | NCT07430306 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | Drug | Preclinical | Transthyretin Amyloidosis | RECRUITING | NCT06465810 |
| Anifrolumab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | RECRUITING | NCT07430306 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | Drug | Preclinical | Transthyretin Amyloidosis | RECRUITING | NCT06465810 |
| Anifrolumab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | RECRUITING | NCT07430306 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | Drug | Preclinical | Transthyretin Amyloidosis | RECRUITING | NCT06465810 |
| Anifrolumab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | RECRUITING | NCT07430306 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | Drug | Preclinical | Transthyretin Amyloidosis | RECRUITING | NCT06465810 |
| Anifrolumab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | RECRUITING | NCT07430306 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | Drug | Preclinical | Transthyretin Amyloidosis | RECRUITING | NCT06465810 |
| Anifrolumab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | RECRUITING | NCT07430306 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | Drug | Preclinical | Transthyretin Amyloidosis | RECRUITING | NCT06465810 |
| Anifrolumab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | RECRUITING | NCT07430306 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | Drug | Preclinical | Transthyretin Amyloidosis | RECRUITING | NCT06465810 |
| Anifrolumab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | RECRUITING | NCT07430306 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | Drug | Preclinical | Transthyretin Amyloidosis | RECRUITING | NCT06465810 |
| Anifrolumab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | RECRUITING | NCT07430306 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | Drug | Preclinical | Transthyretin Amyloidosis | RECRUITING | NCT06465810 |
| Anifrolumab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | RECRUITING | NCT07430306 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | Drug | Preclinical | Transthyretin Amyloidosis | RECRUITING | NCT06465810 |
| Anifrolumab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | RECRUITING | NCT07430306 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | Drug | Preclinical | Transthyretin Amyloidosis | RECRUITING | NCT06465810 |
| Anifrolumab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | RECRUITING | NCT07430306 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | Drug | Preclinical | Transthyretin Amyloidosis | RECRUITING | NCT06465810 |
| Anifrolumab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | RECRUITING | NCT07430306 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | Drug | Preclinical | Transthyretin Amyloidosis | RECRUITING | NCT06465810 |
| Anifrolumab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | RECRUITING | NCT07430306 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | Drug | Preclinical | Transthyretin Amyloidosis | RECRUITING | NCT06465810 |
| Anifrolumab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | RECRUITING | NCT07430306 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | Drug | Preclinical | Transthyretin Amyloidosis | RECRUITING | NCT06465810 |
| Anifrolumab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | RECRUITING | NCT07430306 |
| Prednisolone | Other | Phase PHASE3 | Cataract | COMPLETED | NCT02547623 |
| Dexamethasone | Other | Phase PHASE3 | Cataract | COMPLETED | NCT02547623 |
| MRI | Other | Approved | Concussion | COMPLETED | NCT02556177 |
| 1805AB | Other | Approved | Tobacco Use | COMPLETED | NCT03688776 |
| 1805AA | Other | Approved | Tobacco Use | COMPLETED | NCT03688776 |
| Placebo | Other | Phase PHASE2 | COVID-19 | UNKNOWN | NCT04646603 |
| MRG-001 | Other | Phase PHASE2 | COVID-19 | UNKNOWN | NCT04646603 |
| 15 MBq/kg Betalutin | Other | Phase PHASE1 | Non Hodgkin Lymphoma | COMPLETED | NCT03806179 |
| 10 MBq/kg Betalutin | Other | Phase PHASE1 | Non Hodgkin Lymphoma | COMPLETED | NCT03806179 |
| HARPOON Beating Heart Mitral Valve Repair System (MVRS) | Other | Approved | Severe Degenerative Mitral Regurgitation Due to Mid-segment Posterior Leaflet Prolapse | TERMINATED | NCT04393779 |
| Placebo | Other | Phase PHASE1 | COVID-19 | WITHDRAWN | NCT06274853 |
| GS-441524 | Other | Phase PHASE1 | COVID-19 | WITHDRAWN | NCT06274853 |
| Placebo | Other | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT01350362 |
| tideglusib | Other | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT01350362 |
| Oral Iron (Ferrous sulphate) | Other | Phase PHASE3 | Iron Deficiency Anaemia | COMPLETED | NCT00994318 |
| FCM (Ferric carboxymaltose) low ferritin target | Other | Phase PHASE3 | Iron Deficiency Anaemia | COMPLETED | NCT00994318 |
| FCM (Ferric carboxymaltose) high ferritin target | Other | Phase PHASE3 | Iron Deficiency Anaemia | COMPLETED | NCT00994318 |
| IBI-10090 | Other | Phase PHASE2 | Inflammation Associated With Cataract Surgery | COMPLETED | NCT01606735 |
| IBI-20089/Lucentis | Other | Phase PHASE1 | Age-Related Macular Degeneration | COMPLETED | NCT01175395 |
| Placebo (saline) | Other | Phase PHASE4 | Iron Deficiency | COMPLETED | NCT01453608 |
| Ferinject (ferric carboxymaltose) | Other | Phase PHASE4 | Iron Deficiency | COMPLETED | NCT01453608 |
| placebo saline | Other | Phase PHASE1 | Insulin Resistance | UNKNOWN | NCT02518932 |
| Last 5 amino acids of GLP-1 | Other | Phase PHASE1 | Insulin Resistance | UNKNOWN | NCT02518932 |
| Recombinant human apolipoprotein(a) Kringle V | Other | Phase PHASE1 | Solid Tumors | TERMINATED | NCT01809912 |
| Sham injection | Other | Phase PHASE3 | Lower Extremity Chronic Ulcers in Diabetics | COMPLETED | NCT01421966 |
| CureXcell® | Other | Phase PHASE3 | Lower Extremity Chronic Ulcers in Diabetics | COMPLETED | NCT01421966 |
| Saline | Other | Phase PHASE2 | Hidradenitis Suppurativa | TERMINATED | NCT01838499 |
| MEDI8968 | Other | Phase PHASE2 | Hidradenitis Suppurativa | TERMINATED | NCT01838499 |
| Deflazacort | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02485431 |
| Intravenous Carbamazepine (IV CBZ) | Other | Phase PHASE3 | Epilepsy | COMPLETED | NCT01128959 |
| Interactive, shortened consent form | Other | Approved | Consent Forms | COMPLETED | NCT03416907 |
| Shortened consent form with a highlights box | Other | Approved | Consent Forms | COMPLETED | NCT03416907 |
| Reordered, shortened consent form | Other | Approved | Consent Forms | COMPLETED | NCT03416907 |
| Shortened consent form | Other | Approved | Consent Forms | COMPLETED | NCT03416907 |
| Original consent form | Other | Approved | Consent Forms | COMPLETED | NCT03416907 |
| MMV390048 | Other | Phase PHASE1 | Malaria,Falciparum | WITHDRAWN | NCT03195387 |
| Placebo | Other | Phase PHASE3 | Inflammation | COMPLETED | NCT02006888 |
| IBI-10090 | Other | Phase PHASE3 | Inflammation | COMPLETED | NCT02006888 |
| Neurological MRI | Other | Approved | Clinical Indication for Brain MRI | COMPLETED | NCT02596854 |
| Procedure/Surgery: Biofluid samplings | Procedure | Preclinical | Parkinson Disease | COMPLETED | NCT03170063 |
| LTX-315 + pembrolizumab | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01986426 |
| LTX-315 + ipilimumab | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01986426 |
| LTX-315 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01986426 |
| LTX-315 consecutive lesions | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01986426 |
| No intervention | Other | Preclinical | Generalized Arterial Calcification in Infancy | UNKNOWN | NCT03758534 |
| IBI-10090 | Other | Phase PHASE2 | Inflammatory Reaction Due to Ocular Lens Prosthesis | TERMINATED | NCT01048593 |
| fecal calprotectin level | Other | Preclinical | Inflammatory Bowel Disease | COMPLETED | NCT02351635 |
| Post-Therapy | Drug | Preclinical | Helicobacter Pylori Infection | COMPLETED | NCT03060733 |
| Tivantinib (ARQ 197) Capsule D, oral | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01149720 |
| Tivantinib (ARQ 197) Tablet | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01149720 |
| Tivantinib (ARQ 197) Capsule | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01149720 |
| Thyroid blocking | Other | Phase PHASE3 | Heart Failure | TERMINATED | NCT02656329 |
| Implantable Cardioverter Defibrillator | Other | Phase PHASE3 | Heart Failure | TERMINATED | NCT02656329 |
| Iobenguane I -123 Injection | Other | Phase PHASE3 | Heart Failure | TERMINATED | NCT02656329 |
| Antroquinonol | Other | Phase PHASE2 | Non-small Cell Lung Cancer Stage IV | COMPLETED | NCT02047344 |
| Online DCE survey | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03046069 |
| Modified DCE | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03046069 |
| DCE surveys- cognitive interviews | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03046069 |
| In-person focus groups | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03046069 |
| Telephone interviews | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03046069 |
| Placebo | Other | Phase PHASE2 | Stress, Psychological | COMPLETED | NCT04125810 |
| Probiotic | Other | Phase PHASE2 | Stress, Psychological | COMPLETED | NCT04125810 |
| Placebo | Other | Phase PHASE1 | Critical Limb Ischemia | COMPLETED | NCT03680105 |
| RJX | Other | Phase PHASE1 | Critical Limb Ischemia | COMPLETED | NCT03680105 |
| Placebo | Other | Phase PHASE2 | Reperfusion Injury | COMPLETED | NCT01572909 |
| Bendavia (MTP-131) | Other | Phase PHASE2 | Reperfusion Injury | COMPLETED | NCT01572909 |
| Placebo | Other | Phase PHASE2 | Premature Ejaculation | COMPLETED | NCT02232425 |
| IX-01 | Other | Phase PHASE2 | Premature Ejaculation | COMPLETED | NCT02232425 |
| Placebo | Other | Phase PHASE3 | Infections | COMPLETED | NCT02802059 |
| EcN-Suspension | Other | Phase PHASE3 | Infections | COMPLETED | NCT02802059 |
| no intervention (post study follow up) | Other | Preclinical | Cancer of the Prostate | COMPLETED | NCT04017325 |
| placebo | Other | Phase PHASE2 | Tibial Fracture | UNKNOWN | NCT04432389 |
| ALLOB | Other | Phase PHASE2 | Tibial Fracture | UNKNOWN | NCT04432389 |
| Saline | Other | Phase PHASE3 | Traumatic Brain Injury | COMPLETED | NCT02794168 |
| VAS203 | Other | Phase PHASE3 | Traumatic Brain Injury | COMPLETED | NCT02794168 |
| The Pine Trees Health Test System | Other | Preclinical | SARS (Severe Acute Respiratory Syndrome) | COMPLETED | NCT05107258 |
| Newly Diagnosed | Other | Preclinical | Helicobacter Pylori Infection | COMPLETED | NCT03060746 |
| Vehicle | Other | Phase PHASE3 | Radiation-induced Oesophagitis | TERMINATED | NCT01336530 |
| magnesium and aluminium hydroxide | Other | Phase PHASE3 | Radiation-induced Oesophagitis | TERMINATED | NCT01336530 |
| oxetacaine | Other | Phase PHASE3 | Radiation-induced Oesophagitis | TERMINATED | NCT01336530 |
| oxetacaine, aluminium and magnesium hydroxide | Other | Phase PHASE3 | Radiation-induced Oesophagitis | TERMINATED | NCT01336530 |
| Proof Lab Test System | Other | Preclinical | COVID-19 | COMPLETED | NCT05331976 |
| Product D | Other | Approved | Smoking | COMPLETED | NCT04094363 |
| Product C | Other | Approved | Smoking | COMPLETED | NCT04094363 |
| Product B | Other | Approved | Smoking | COMPLETED | NCT04094363 |
| Product A | Other | Approved | Smoking | COMPLETED | NCT04094363 |
| cAd3-EBO-S | Other | Phase PHASE1 | Ebola Virus Disease | COMPLETED | NCT04723602 |
| cAd3-Marburg | Other | Phase PHASE1 | Ebola Virus Disease | COMPLETED | NCT04723602 |
| Imgatuzumab | Other | Phase PHASE2 | Cutaneous Squamous Cell Carcinoma | WITHDRAWN | NCT04985825 |
| S.opt.FL COVID-19 pDNA vaccine | Other | Phase PHASE1 | Safety | UNKNOWN | NCT05171946 |
| Placebo | Other | Phase PHASE1 | Neuroinflammatory Response | COMPLETED | NCT05429840 |
| MT1980 | Other | Phase PHASE1 | Neuroinflammatory Response | COMPLETED | NCT05429840 |
| Dasatinib | Other | Phase PHASE2 | Chronic Phase Chronic Myeloid Leukemia | COMPLETED | NCT01850004 |
| Cohort 3 Probe Substrate Cocktail | Other | Phase PHASE1 | Drug Interaction | COMPLETED | NCT05334108 |
| Cohort 2 Probe Substrate | Other | Phase PHASE1 | Drug Interaction | COMPLETED | NCT05334108 |
| Cohort 1 Probe Substrate Cocktail | Other | Phase PHASE1 | Drug Interaction | COMPLETED | NCT05334108 |
| Ecopipam | Other | Phase PHASE1 | Drug Interaction | COMPLETED | NCT05334108 |
| Microlife WatchBP Home A | Other | Approved | Atrial Fibrillation | COMPLETED | NCT05599308 |
| OMRON blood pressure monitor with AFib screening feature | Other | Approved | Atrial Fibrillation | COMPLETED | NCT05599308 |
| Dasatinib | Other | Phase PHASE2 | Chronic Phase Chronic Myeloid Leukemia | COMPLETED | NCT01593254 |
| Imatinib | Other | Phase PHASE2 | Chronic Phase Chronic Myeloid Leukemia | COMPLETED | NCT01593254 |
| best practice VTE prophylaxis | Other | Approved | Pulmonary Embolism | ACTIVE_NOT_RECRUITING | NCT05127915 |
| Adient absorbable filter + best practice VTE prophylaxis | Other | Approved | Pulmonary Embolism | ACTIVE_NOT_RECRUITING | NCT05127915 |
| FP-101 | Other | Phase PHASE2 | Vasomotor Symptoms | COMPLETED | NCT05312567 |
| H1 influenza antigen | Other | Phase PHASE1 | Influenza | COMPLETED | NCT06125717 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05723692 |
| ALTB-268 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05723692 |
| Video Informed consent information | Other | Approved | Consent Forms | COMPLETED | NCT02489682 |
| Short-form written Informed consent information | Other | Approved | Consent Forms | COMPLETED | NCT02489682 |
| Long-form written Informed consent information | Other | Approved | Consent Forms | COMPLETED | NCT02489682 |
| Vimizim® (elosulfase alfa) | Other | Preclinical | Mucopolysaccharidosis IV Type A | COMPLETED | NCT02294877 |
| Pemetrexed | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04622007 |
| Pembrolizumab | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04622007 |
| Tomivosertib | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04622007 |
| Control (palpation) | Other | Approved | Central Nervous System Infections | COMPLETED | NCT04796935 |
| Tactile Imaging (VerTouch) | Other | Approved | Central Nervous System Infections | COMPLETED | NCT04796935 |
| 12.5 mBq/kg Betalutin | Other | Phase PHASE1 | Non-Hodgkin Lymphoma | COMPLETED | NCT01796171 |
| Rituximab | Other | Phase PHASE1 | Non-Hodgkin Lymphoma | COMPLETED | NCT01796171 |
| 60 mg/m2 lilotomab | Other | Phase PHASE1 | Non-Hodgkin Lymphoma | COMPLETED | NCT01796171 |
| 100 mg/m2 lilotomab | Other | Phase PHASE1 | Non-Hodgkin Lymphoma | COMPLETED | NCT01796171 |
| 40 mg lilotomab | Other | Phase PHASE1 | Non-Hodgkin Lymphoma | COMPLETED | NCT01796171 |
| 20 MBq/kg Betalutin | Other | Phase PHASE1 | Non-Hodgkin Lymphoma | COMPLETED | NCT01796171 |
| 15 MBq/kg Betalutin | Other | Phase PHASE1 | Non-Hodgkin Lymphoma | COMPLETED | NCT01796171 |
| 10 MBq/kg Betalutin | Other | Phase PHASE1 | Non-Hodgkin Lymphoma | COMPLETED | NCT01796171 |
| D5W Placebo | Other | Phase PHASE3 | Chemotherapy-induced Neutropenia | COMPLETED | NCT03102606 |
| Saline Placebo | Other | Phase PHASE3 | Chemotherapy-induced Neutropenia | COMPLETED | NCT03102606 |
| Pegfilgrastim | Other | Phase PHASE3 | Chemotherapy-induced Neutropenia | COMPLETED | NCT03102606 |
| Plinabulin | Other | Phase PHASE3 | Chemotherapy-induced Neutropenia | COMPLETED | NCT03102606 |
| Autologous genetically modified ADP-A2M4CD8 cells | Other | Phase PHASE2 | Esophageal Cancer | TERMINATED | NCT04752358 |
| Active Control (Shingrix) | Other | Phase PHASE1 | Herpes Zoster (HZ) | COMPLETED | NCT05871541 |
| JCXH-105 | Other | Phase PHASE1 | Herpes Zoster (HZ) | COMPLETED | NCT05871541 |
| Placebo | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05743335 |
| JCXH-221 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05743335 |
| Factor VIII | Other | Preclinical | Hemophilia A | COMPLETED | NCT02976753 |
| efmoroctocog alfa | Other | Preclinical | Hemophilia A | COMPLETED | NCT02976753 |
| Transcatheter Mitral Valve Replacement | Other | Approved | Mitral Valve Regurgitation | COMPLETED | NCT02974881 |
| Placebo | Other | Phase PHASE1 | Metastatic Colorectal Carcinoma | ACTIVE_NOT_RECRUITING | NCT05322590 |
| BXQ-350 | Other | Phase PHASE1 | Metastatic Colorectal Carcinoma | ACTIVE_NOT_RECRUITING | NCT05322590 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT06401213 |
| MTX-463 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT06401213 |
| Progesterone | Other | Phase PHASE3 | Vasomotor Symptoms | COMPLETED | NCT04209543 |
| Placebo | Other | Phase PHASE3 | Vasomotor Symptoms | COMPLETED | NCT04209543 |
| Estetrol | Other | Phase PHASE3 | Vasomotor Symptoms | COMPLETED | NCT04209543 |
| Nivolumab | Other | Phase PHASE1 | Solid Tumor, Adult | COMPLETED | NCT04761198 |
| Etigilimab | Other | Phase PHASE1 | Solid Tumor, Adult | COMPLETED | NCT04761198 |
| Surgical Repair | Other | Preclinical | Vascular Aneurysm | ACTIVE_NOT_RECRUITING | NCT05721001 |
| MB-CART2019.1 Dose level 2 | Other | Phase PHASE1 | B-cell Non Hodgkin Lymphoma | COMPLETED | NCT03870945 |
| MB-CART2019.1 Dose level 1 | Other | Phase PHASE1 | B-cell Non Hodgkin Lymphoma | COMPLETED | NCT03870945 |
| FFP/Cryo | Other | Phase PHASE3 | Bleeding Disorder | COMPLETED | NCT03444324 |
| BT524 | Other | Phase PHASE3 | Bleeding Disorder | COMPLETED | NCT03444324 |
| BT524 (Part II) | Other | Phase PHASE3 | Congenital Afibrinogenemia | COMPLETED | NCT02065882 |
| BT524 (Part I) | Other | Phase PHASE3 | Congenital Afibrinogenemia | COMPLETED | NCT02065882 |
| Physiologic saline solution | Other | Phase PHASE3 | Antibody-mediated Rejection | TERMINATED | NCT03744910 |
| Clazakizumab | Other | Phase PHASE3 | Antibody-mediated Rejection | TERMINATED | NCT03744910 |
| Jatenzo | Other | Phase PHASE4 | Hypogonadism | ACTIVE_NOT_RECRUITING | NCT06385509 |
| HighLife Transcatheter Mitral Valve Replacement | Other | Approved | Mitral Regurgitation | RECRUITING | NCT04029363 |
| SP-420 | Other | Phase PHASE2 | Beta Thalassemia Major Anemia | RECRUITING | NCT05693909 |
| Belimumab | Other | Phase PHASE3 | Connective Tissue Diseases | RECRUITING | NCT06716606 |
| Placebo | Other | Phase PHASE2 | Hypochondroplasia | RECRUITING | NCT07126262 |
| Vosoritide | Other | Phase PHASE2 | Hypochondroplasia | RECRUITING | NCT07126262 |
| Petrelintide | Other | Phase PHASE1 | Obesity & Overweight | COMPLETED | NCT07338214 |
| Tasipimidine placebo | Other | Phase PHASE2 | Insomnia | COMPLETED | NCT06956495 |
| Tasipimidine | Other | Phase PHASE2 | Insomnia | COMPLETED | NCT06956495 |
| Peripheral Orbital Atherectomy System (OAS) | Other | Approved | Peripheral Artery Disease | COMPLETED | NCT05529472 |
| MMV367 1500mg | Other | Phase PHASE1 | Infections | COMPLETED | NCT05979207 |
| MMV367 90mg | Other | Phase PHASE1 | Infections | COMPLETED | NCT05979207 |
| MMV367 20mg | Other | Phase PHASE1 | Infections | COMPLETED | NCT05979207 |
| MMV367 10mg | Other | Phase PHASE1 | Infections | COMPLETED | NCT05979207 |
| MMV367 5mg | Other | Phase PHASE1 | Infections | COMPLETED | NCT05979207 |
| P. falciparum IBSM infection | Other | Phase PHASE1 | Infections | COMPLETED | NCT05979207 |
| MMV367 3mg | Other | Phase PHASE1 | Infections | COMPLETED | NCT05979207 |
| Durvalumab-based combination therapies in observational study setting | Other | Preclinical | Hepatobiliary Cancers | RECRUITING | NCT06252753 |
| On ibalizumab treatment | Drug | Preclinical | HIV Infections | ACTIVE_NOT_RECRUITING | NCT05388474 |
| No ibalizumab or Pre-ibalizumab treatment | Drug | Preclinical | HIV Infections | ACTIVE_NOT_RECRUITING | NCT05388474 |
| 15 µg H5N1 antigen plus MF59 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| 7.5 µg H5N1 antigen plus MF59 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| 3.75 µg H5N1 antigen plus MF59 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| 15 µg H5N1 antigen plus full dose AS03A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| 7.5 µg H5N1 antigen plus full dose AS03A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| 3.75 µg H5N1 antigen plus full dose AS03A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| 15 µg H5N8 antigen plus MF59 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| 7.5 µg H5N8 antigen plus MF59 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| 3.75 µg H5N8 antigen plus MF59 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| 15 µg H5N8 antigen plus half dose AS03A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| 7.5 µg H5N8 antigen plus half dose AS03A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| 3.75 µg H5N8 antigen plus half dose AS03A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| 15 µg H5N8 antigen plus full dose AS03A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| 7.5 µg H5N8 antigen plus full dose AS03A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| 3.75 µg H5N8 antigen plus full dose AS03A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| chlorpheniramine | Other | Phase PHASE2 | Hepatitis B, Chronic | TERMINATED | NCT02065336 |
| entecavir | Other | Phase PHASE2 | Hepatitis B, Chronic | TERMINATED | NCT02065336 |
| Placebo | Other | Phase PHASE2 | Hepatitis B, Chronic | TERMINATED | NCT02065336 |
| ARC-520 | Other | Phase PHASE2 | Hepatitis B, Chronic | TERMINATED | NCT02065336 |
| Tasso+™ | Other | Approved | Healthy | COMPLETED | NCT06507566 |
| Petrelintide | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT07076030 |
| padeliporfin VTP | Other | Phase PHASE3 | Transitional Cell Cancer of Renal Pelvis and Ureter | RECRUITING | NCT04620239 |
| Placebo Capsules | Other | Phase PHASE2 | Chronic Heart Failure | ACTIVE_NOT_RECRUITING | NCT06017609 |
| JTT-861 Capsules | Other | Phase PHASE2 | Chronic Heart Failure | ACTIVE_NOT_RECRUITING | NCT06017609 |
| Anifrolumab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | NOT_YET_RECRUITING | NCT07430306 |
| Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL) | Other | Phase PHASE2 | Anthrax | ACTIVE_NOT_RECRUITING | NCT05997264 |
| Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL) | Other | Phase PHASE2 | Anthrax | ACTIVE_NOT_RECRUITING | NCT05997264 |
| AV7909 Half Dose (0.25 mL) | Other | Phase PHASE2 | Anthrax | ACTIVE_NOT_RECRUITING | NCT05997264 |
| AV7909 Full Dose (0.5 mL) | Other | Phase PHASE2 | Anthrax | ACTIVE_NOT_RECRUITING | NCT05997264 |
| Kedrion IVIG 10% | Other | Phase PHASE3 | Chronic Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT07059000 |
| Vehicle solution | Other | Phase PHASE3 | Alopecia, Androgenetic | ACTIVE_NOT_RECRUITING | NCT05910450 |
| Clascoterone 5% solution | Other | Phase PHASE3 | Alopecia, Androgenetic | ACTIVE_NOT_RECRUITING | NCT05910450 |
| PRX-102 2 mg/kg every 4 weeks | Other | Phase PHASE2 | Fabry Disease | RECRUITING | NCT05710692 |
| PRX-102 1 mg/kg every 2 weeks | Other | Phase PHASE2 | Fabry Disease | RECRUITING | NCT05710692 |
| Not applicable- observational study | Other | Preclinical | Fabry Disease | RECRUITING | NCT06941025 |
| PRX-102 1 mg/kg every two weeks | Other | Phase PHASE2 | Fabry Disease | RECRUITING | NCT06328608 |
| Tafenoquine (TQ) | Other | Preclinical | Malaria, Vivax | COMPLETED | NCT05361486 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | Drug | Preclinical | Transthyretin Amyloidosis | RECRUITING | NCT06465810 |
| MVA-BN (Quail) | Other | Phase PHASE2 | Monkeypox (Mpox) | ACTIVE_NOT_RECRUITING | NCT07199569 |
| Jynneos | Other | Phase PHASE2 | Monkeypox (Mpox) | ACTIVE_NOT_RECRUITING | NCT07199569 |
| Standard of Care | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | RECRUITING | NCT04844866 |
| MB-CART2019.1 | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | RECRUITING | NCT04844866 |
| Standard of Care | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | RECRUITING | NCT04844866 |
| MB-CART2019.1 | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | RECRUITING | NCT04844866 |
| Standard of Care | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | RECRUITING | NCT04844866 |
| MB-CART2019.1 | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | RECRUITING | NCT04844866 |
| Standard of Care | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | RECRUITING | NCT04844866 |
| MB-CART2019.1 | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | RECRUITING | NCT04844866 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04883333 |
| LEO 153339 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04883333 |
| Standard of Care | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | RECRUITING | NCT04844866 |
| MB-CART2019.1 | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | RECRUITING | NCT04844866 |
| Standard of Care | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | RECRUITING | NCT04844866 |
| MB-CART2019.1 | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | RECRUITING | NCT04844866 |
| Standard of Care | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | RECRUITING | NCT04844866 |
| MB-CART2019.1 | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | RECRUITING | NCT04844866 |
| Standard of Care | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | RECRUITING | NCT04844866 |
| MB-CART2019.1 | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | RECRUITING | NCT04844866 |
| Standard of Care | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | RECRUITING | NCT04844866 |
| MB-CART2019.1 | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | RECRUITING | NCT04844866 |
| Standard of Care | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | RECRUITING | NCT04844866 |
| MB-CART2019.1 | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | RECRUITING | NCT04844866 |
| Standard of Care | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | RECRUITING | NCT04844866 |
| MB-CART2019.1 | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | RECRUITING | NCT04844866 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04883333 |
| LEO 153339 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04883333 |
| Standard of Care | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | RECRUITING | NCT04844866 |
| MB-CART2019.1 | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | RECRUITING | NCT04844866 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04883333 |
| LEO 153339 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04883333 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04883333 |
| LEO 153339 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04883333 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04883333 |
| LEO 153339 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04883333 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04883333 |
| LEO 153339 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04883333 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04883333 |
| LEO 153339 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04883333 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04883333 |
| LEO 153339 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04883333 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04883333 |
| LEO 153339 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04883333 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04883333 |
| LEO 153339 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04883333 |
| Napazimone | DRUG | Phase PHASE2 | Mitochondrial Diseases | NOT_YET_RECRUITING | NCT07514338 |
| Anifrolumab | DRUG | Phase PHASE3 | Systemic Lupus Erythematosus | NOT_YET_RECRUITING | NCT07430306 |
| MVA-BN (Quail) | BIOLOGICAL | Phase PHASE2 | Monkeypox (Mpox) | ACTIVE_NOT_RECRUITING | NCT07199569 |
| Jynneos | BIOLOGICAL | Phase PHASE2 | Monkeypox (Mpox) | ACTIVE_NOT_RECRUITING | NCT07199569 |
| Vosoritide | DRUG | Phase PHASE2 | Hypochondroplasia | RECRUITING | NCT07126262 |
| Petrelintide | DRUG | Phase PHASE1 | Obesity & Overweight | COMPLETED | NCT07338214 |
| Kedrion IVIG 10% | BIOLOGICAL | Phase PHASE3 | Chronic Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT07059000 |
| Not applicable- observational study | OTHER | Preclinical | Fabry Disease | RECRUITING | NCT06941025 |
| Belimumab | DRUG | Phase PHASE3 | Connective Tissue Diseases | RECRUITING | NCT06716606 |
| 15 µg H5N1 antigen plus MF59 | BIOLOGICAL | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| 7.5 µg H5N1 antigen plus MF59 | BIOLOGICAL | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| 3.75 µg H5N1 antigen plus MF59 | BIOLOGICAL | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| 15 µg H5N1 antigen plus full dose AS03A | BIOLOGICAL | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| 7.5 µg H5N1 antigen plus full dose AS03A | BIOLOGICAL | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| 3.75 µg H5N1 antigen plus full dose AS03A | BIOLOGICAL | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| 15 µg H5N8 antigen plus MF59 | BIOLOGICAL | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| 7.5 µg H5N8 antigen plus MF59 | BIOLOGICAL | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| 3.75 µg H5N8 antigen plus MF59 | BIOLOGICAL | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| 15 µg H5N8 antigen plus half dose AS03A | BIOLOGICAL | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| 7.5 µg H5N8 antigen plus half dose AS03A | BIOLOGICAL | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| 3.75 µg H5N8 antigen plus half dose AS03A | BIOLOGICAL | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| 15 µg H5N8 antigen plus full dose AS03A | BIOLOGICAL | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| 7.5 µg H5N8 antigen plus full dose AS03A | BIOLOGICAL | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| 3.75 µg H5N8 antigen plus full dose AS03A | BIOLOGICAL | Phase PHASE2 | Influenza | COMPLETED | NCT06560151 |
| Tasso+™ | DEVICE | Approved | Healthy | COMPLETED | NCT06507566 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | DRUG | Preclinical | Transthyretin Amyloidosis | RECRUITING | NCT06465810 |
| MTX-463 | BIOLOGICAL | Phase PHASE1 | Healthy | COMPLETED | NCT06401213 |
| Jatenzo | DRUG | Phase PHASE4 | Hypogonadism | ACTIVE_NOT_RECRUITING | NCT06385509 |
| PRX-102 1 mg/kg every two weeks | DRUG | Phase PHASE2 | Fabry Disease | RECRUITING | NCT06328608 |
| GS-441524 | DRUG | Phase PHASE1 | COVID-19 | WITHDRAWN | NCT06274853 |
| Durvalumab-based combination therapies in observational study setting | OTHER | Preclinical | Hepatobiliary Cancers | RECRUITING | NCT06252753 |
| H1 influenza antigen | BIOLOGICAL | Phase PHASE1 | Influenza | COMPLETED | NCT06125717 |
| Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL) | BIOLOGICAL | Phase PHASE2 | Anthrax | ACTIVE_NOT_RECRUITING | NCT05997264 |
| Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL) | BIOLOGICAL | Phase PHASE2 | Anthrax | ACTIVE_NOT_RECRUITING | NCT05997264 |
| AV7909 Half Dose (0.25 mL) | BIOLOGICAL | Phase PHASE2 | Anthrax | ACTIVE_NOT_RECRUITING | NCT05997264 |
| AV7909 Full Dose (0.5 mL) | BIOLOGICAL | Phase PHASE2 | Anthrax | ACTIVE_NOT_RECRUITING | NCT05997264 |
| MMV367 1500mg | DRUG | Phase PHASE1 | Infections | COMPLETED | NCT05979207 |
| MMV367 90mg | DRUG | Phase PHASE1 | Infections | COMPLETED | NCT05979207 |
| MMV367 20mg | DRUG | Phase PHASE1 | Infections | COMPLETED | NCT05979207 |
| MMV367 10mg | DRUG | Phase PHASE1 | Infections | COMPLETED | NCT05979207 |
| MMV367 5mg | DRUG | Phase PHASE1 | Infections | COMPLETED | NCT05979207 |
| P. falciparum IBSM infection | OTHER | Phase PHASE1 | Infections | COMPLETED | NCT05979207 |
| MMV367 3mg | DRUG | Phase PHASE1 | Infections | COMPLETED | NCT05979207 |
| Active Control (Shingrix) | BIOLOGICAL | Phase PHASE1 | Herpes Zoster (HZ) | COMPLETED | NCT05871541 |
| JCXH-105 | BIOLOGICAL | Phase PHASE1 | Herpes Zoster (HZ) | COMPLETED | NCT05871541 |
| JCXH-221 | BIOLOGICAL | Phase PHASE1 | COVID-19 | COMPLETED | NCT05743335 |
| ALTB-268 | BIOLOGICAL | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05723692 |
| Surgical Repair | DEVICE | Preclinical | Vascular Aneurysm | ACTIVE_NOT_RECRUITING | NCT05721001 |
| PRX-102 2 mg/kg every 4 weeks | DRUG | Phase PHASE2 | Fabry Disease | RECRUITING | NCT05710692 |
| PRX-102 1 mg/kg every 2 weeks | DRUG | Phase PHASE2 | Fabry Disease | RECRUITING | NCT05710692 |
| SP-420 | DRUG | Phase PHASE2 | Beta Thalassemia Major Anemia | RECRUITING | NCT05693909 |
| Microlife WatchBP Home A | DEVICE | Approved | Atrial Fibrillation | COMPLETED | NCT05599308 |
| OMRON blood pressure monitor with AFib screening feature | DEVICE | Approved | Atrial Fibrillation | COMPLETED | NCT05599308 |
| Peripheral Orbital Atherectomy System (OAS) | DEVICE | Approved | Peripheral Artery Disease | COMPLETED | NCT05529472 |
| MT1980 | DRUG | Phase PHASE1 | Neuroinflammatory Response | COMPLETED | NCT05429840 |
| On ibalizumab treatment | BIOLOGICAL | Preclinical | HIV Infections | ACTIVE_NOT_RECRUITING | NCT05388474 |
| No ibalizumab or Pre-ibalizumab treatment | OTHER | Preclinical | HIV Infections | ACTIVE_NOT_RECRUITING | NCT05388474 |
| Tafenoquine (TQ) | DRUG | Preclinical | Malaria, Vivax | COMPLETED | NCT05361486 |
| BXQ-350 | DRUG | Phase PHASE1 | Metastatic Colorectal Carcinoma | ACTIVE_NOT_RECRUITING | NCT05322590 |
| FP-101 | DRUG | Phase PHASE2 | Vasomotor Symptoms | COMPLETED | NCT05312567 |
| S.opt.FL COVID-19 pDNA vaccine | DRUG | Phase PHASE1 | Safety | UNKNOWN | NCT05171946 |
| best practice VTE prophylaxis | DEVICE | Approved | Pulmonary Embolism | ACTIVE_NOT_RECRUITING | NCT05127915 |
| Adient absorbable filter + best practice VTE prophylaxis | DEVICE | Approved | Pulmonary Embolism | ACTIVE_NOT_RECRUITING | NCT05127915 |
| Imgatuzumab | DRUG | Phase PHASE2 | Cutaneous Squamous Cell Carcinoma | WITHDRAWN | NCT04985825 |
| LEO 153339 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04883333 |
| MB-CART2019.1 | GENETIC | Phase PHASE2 | Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04844866 |
| Control (palpation) | OTHER | Approved | Central Nervous System Infections | COMPLETED | NCT04796935 |
| Tactile Imaging (VerTouch) | DEVICE | Approved | Central Nervous System Infections | COMPLETED | NCT04796935 |
| Nivolumab | DRUG | Phase PHASE1 | Solid Tumor, Adult | COMPLETED | NCT04761198 |
| Etigilimab | DRUG | Phase PHASE1 | Solid Tumor, Adult | COMPLETED | NCT04761198 |
| Autologous genetically modified ADP-A2M4CD8 cells | GENETIC | Phase PHASE2 | Esophageal Cancer | TERMINATED | NCT04752358 |
| cAd3-EBO-S | BIOLOGICAL | Phase PHASE1 | Ebola Virus Disease | COMPLETED | NCT04723602 |
| cAd3-Marburg | BIOLOGICAL | Phase PHASE1 | Ebola Virus Disease | COMPLETED | NCT04723602 |
| MRG-001 | DRUG | Phase PHASE2 | COVID-19 | UNKNOWN | NCT04646603 |
| Pemetrexed | DRUG | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04622007 |
| Pembrolizumab | BIOLOGICAL | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04622007 |
| Tomivosertib | DRUG | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04622007 |
| padeliporfin VTP | DRUG | Phase PHASE3 | Transitional Cell Cancer of Renal Pelvis and Ureter | RECRUITING | NCT04620239 |
| placebo | OTHER | Phase PHASE2 | Tibial Fracture | UNKNOWN | NCT04432389 |
| ALLOB | BIOLOGICAL | Phase PHASE2 | Tibial Fracture | UNKNOWN | NCT04432389 |
| HARPOON Beating Heart Mitral Valve Repair System (MVRS) | DEVICE | Approved | Severe Degenerative Mitral Regurgitation Due to Mid-segment Posterior Leaflet Prolapse | TERMINATED | NCT04393779 |
| Probiotic | BIOLOGICAL | Phase PHASE2 | Stress, Psychological | COMPLETED | NCT04125810 |
| Product D | OTHER | Approved | Smoking | COMPLETED | NCT04094363 |
| Product C | OTHER | Approved | Smoking | COMPLETED | NCT04094363 |
| Product B | OTHER | Approved | Smoking | COMPLETED | NCT04094363 |
| Product A | OTHER | Approved | Smoking | COMPLETED | NCT04094363 |
| Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks | GENETIC | Phase PHASE1 | Endometrial Cancer | ACTIVE_NOT_RECRUITING | NCT04044859 |
| HighLife Transcatheter Mitral Valve Replacement | DEVICE | Approved | Mitral Regurgitation | RECRUITING | NCT04029363 |
| no intervention (post study follow up) | OTHER | Preclinical | Cancer of the Prostate | COMPLETED | NCT04017325 |
| MB-CART2019.1 Dose level 2 | BIOLOGICAL | Phase PHASE1 | B-cell Non Hodgkin Lymphoma | COMPLETED | NCT03870945 |
| MB-CART2019.1 Dose level 1 | BIOLOGICAL | Phase PHASE1 | B-cell Non Hodgkin Lymphoma | COMPLETED | NCT03870945 |
| Matching Placebo | DRUG | Phase PHASE1 | Safety | COMPLETED | NCT03830762 |
| Xanamem | DRUG | Phase PHASE1 | Safety | COMPLETED | NCT03830762 |
| No intervention | OTHER | Preclinical | Generalized Arterial Calcification in Infancy | UNKNOWN | NCT03758534 |
| RJX | DRUG | Phase PHASE1 | Critical Limb Ischemia | COMPLETED | NCT03680105 |
| FFP/Cryo | BIOLOGICAL | Phase PHASE3 | Bleeding Disorder | COMPLETED | NCT03444324 |
| BT524 | BIOLOGICAL | Phase PHASE3 | Bleeding Disorder | COMPLETED | NCT03444324 |
| Interactive, shortened consent form | BEHAVIORAL | Approved | Consent Forms | COMPLETED | NCT03416907 |
| Shortened consent form with a highlights box | BEHAVIORAL | Approved | Consent Forms | COMPLETED | NCT03416907 |
| Reordered, shortened consent form | BEHAVIORAL | Approved | Consent Forms | COMPLETED | NCT03416907 |
| Shortened consent form | BEHAVIORAL | Approved | Consent Forms | COMPLETED | NCT03416907 |
| Original consent form | BEHAVIORAL | Approved | Consent Forms | COMPLETED | NCT03416907 |
| MMV390048 | DRUG | Phase PHASE1 | Malaria,Falciparum | WITHDRAWN | NCT03195387 |
| D5W Placebo | OTHER | Phase PHASE3 | Chemotherapy-induced Neutropenia | COMPLETED | NCT03102606 |
| Saline Placebo | OTHER | Phase PHASE3 | Chemotherapy-induced Neutropenia | COMPLETED | NCT03102606 |
| Pegfilgrastim | DRUG | Phase PHASE3 | Chemotherapy-induced Neutropenia | COMPLETED | NCT03102606 |
| Plinabulin | DRUG | Phase PHASE3 | Chemotherapy-induced Neutropenia | COMPLETED | NCT03102606 |
| Online DCE survey | OTHER | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03046069 |
| Modified DCE | OTHER | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03046069 |
| DCE surveys- cognitive interviews | OTHER | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03046069 |
| In-person focus groups | OTHER | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03046069 |
| Telephone interviews | OTHER | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03046069 |
| Factor VIII | DRUG | Preclinical | Hemophilia A | COMPLETED | NCT02976753 |
| efmoroctocog alfa | DRUG | Preclinical | Hemophilia A | COMPLETED | NCT02976753 |
| Transcatheter Mitral Valve Replacement | DEVICE | Approved | Mitral Valve Regurgitation | COMPLETED | NCT02974881 |
| EcN-Suspension | DRUG | Phase PHASE3 | Infections | COMPLETED | NCT02802059 |
| VAS203 | DRUG | Phase PHASE3 | Traumatic Brain Injury | COMPLETED | NCT02794168 |
| Thyroid blocking | DRUG | Phase PHASE3 | Heart Failure | TERMINATED | NCT02656329 |
| Implantable Cardioverter Defibrillator | DEVICE | Phase PHASE3 | Heart Failure | TERMINATED | NCT02656329 |
| Iobenguane I -123 Injection | DRUG | Phase PHASE3 | Heart Failure | TERMINATED | NCT02656329 |
| Neurological MRI | DEVICE | Approved | Clinical Indication for Brain MRI | COMPLETED | NCT02596854 |
| MRI | PROCEDURE | Approved | Concussion | COMPLETED | NCT02556177 |
| Prednisolone | DRUG | Phase PHASE3 | Cataract | COMPLETED | NCT02547623 |
| Dexamethasone | DRUG | Phase PHASE3 | Cataract | COMPLETED | NCT02547623 |
| placebo saline | DRUG | Phase PHASE1 | Insulin Resistance | UNKNOWN | NCT02518932 |
| Last 5 amino acids of GLP-1 | DRUG | Phase PHASE1 | Insulin Resistance | UNKNOWN | NCT02518932 |
| Video Informed consent information | OTHER | Approved | Consent Forms | COMPLETED | NCT02489682 |
| Short-form written Informed consent information | OTHER | Approved | Consent Forms | COMPLETED | NCT02489682 |
| Long-form written Informed consent information | OTHER | Approved | Consent Forms | COMPLETED | NCT02489682 |
| Deflazacort | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02485431 |
| Vimizim® (elosulfase alfa) | DRUG | Preclinical | Mucopolysaccharidosis IV Type A | COMPLETED | NCT02294877 |
| chlorpheniramine | DRUG | Phase PHASE2 | Hepatitis B, Chronic | TERMINATED | NCT02065336 |
| entecavir | DRUG | Phase PHASE2 | Hepatitis B, Chronic | TERMINATED | NCT02065336 |
| ARC-520 | DRUG | Phase PHASE2 | Hepatitis B, Chronic | TERMINATED | NCT02065336 |
| Imatinib | DRUG | Phase PHASE2 | Chronic Phase Chronic Myeloid Leukemia | COMPLETED | NCT01593254 |
| IX-01 | DRUG | Phase PHASE2 | Premature Ejaculation | COMPLETED | NCT02232425 |
| BT524 (Part II) | DRUG | Phase PHASE3 | Congenital Afibrinogenemia | COMPLETED | NCT02065882 |
| BT524 (Part I) | DRUG | Phase PHASE3 | Congenital Afibrinogenemia | COMPLETED | NCT02065882 |
| Antroquinonol | DRUG | Phase PHASE2 | Non-small Cell Lung Cancer Stage IV | COMPLETED | NCT02047344 |
| LTX-315 + pembrolizumab | DRUG | Phase PHASE1 | Cancer | COMPLETED | NCT01986426 |
| LTX-315 + ipilimumab | DRUG | Phase PHASE1 | Cancer | COMPLETED | NCT01986426 |
| LTX-315 | DRUG | Phase PHASE1 | Cancer | COMPLETED | NCT01986426 |
| LTX-315 consecutive lesions | DRUG | Phase PHASE1 | Cancer | COMPLETED | NCT01986426 |
| Dasatinib | DRUG | Phase PHASE2 | Chronic Phase Chronic Myeloid Leukemia | COMPLETED | NCT01850004 |
| Saline | DRUG | Phase PHASE3 | Traumatic Brain Injury | COMPLETED | NCT02794168 |
| MEDI8968 | BIOLOGICAL | Phase PHASE2 | Hidradenitis Suppurativa | TERMINATED | NCT01838499 |
| Bendavia (MTP-131) | DRUG | Phase PHASE2 | Reperfusion Injury | COMPLETED | NCT01572909 |
| Sham injection | BIOLOGICAL | Phase PHASE3 | Lower Extremity Chronic Ulcers in Diabetics | COMPLETED | NCT01421966 |
| CureXcell® | BIOLOGICAL | Phase PHASE3 | Lower Extremity Chronic Ulcers in Diabetics | COMPLETED | NCT01421966 |
| Vehicle | OTHER | Phase PHASE3 | Radiation-induced Oesophagitis | TERMINATED | NCT01336530 |
| magnesium and aluminium hydroxide | DRUG | Phase PHASE3 | Radiation-induced Oesophagitis | TERMINATED | NCT01336530 |
| oxetacaine | DRUG | Phase PHASE3 | Radiation-induced Oesophagitis | TERMINATED | NCT01336530 |
| oxetacaine, aluminium and magnesium hydroxide | DRUG | Phase PHASE3 | Radiation-induced Oesophagitis | TERMINATED | NCT01336530 |
| IBI-10090 | DRUG | Phase PHASE3 | Inflammation | COMPLETED | NCT02006888 |
| IBI-20089/Lucentis | DRUG | Phase PHASE1 | Age-Related Macular Degeneration | COMPLETED | NCT01175395 |
| Intravenous Carbamazepine (IV CBZ) | DRUG | Phase PHASE3 | Epilepsy | COMPLETED | NCT01128959 |
| Oral Iron (Ferrous sulphate) | DRUG | Phase PHASE3 | Iron Deficiency Anaemia | COMPLETED | NCT00994318 |
| FCM (Ferric carboxymaltose) low ferritin target | DRUG | Phase PHASE3 | Iron Deficiency Anaemia | COMPLETED | NCT00994318 |
| FCM (Ferric carboxymaltose) high ferritin target | DRUG | Phase PHASE3 | Iron Deficiency Anaemia | COMPLETED | NCT00994318 |
| Dextrose | DRUG | Phase PHASE4 | Pulmonary Hypertension | COMPLETED | NCT00878878 |
| Optison (Perflutren Protein-Type A Microspheres Injectable Suspension) | DRUG | Phase PHASE4 | Pulmonary Hypertension | COMPLETED | NCT00878878 |
| sNN0029 | DRUG | Phase PHASE1 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT01384162 |
| SMP-986 | DRUG | Phase PHASE2 | Overactive Bladder Syndrome (OABS) | COMPLETED | NCT00409539 |
| Gemcitabine (Chemotherapy) | DRUG | Phase PHASE3 | Advanced Unresectable Pancreatic Cancer | TERMINATED | NCT00358566 |
| GV1001 | BIOLOGICAL | Phase PHASE3 | Advanced Unresectable Pancreatic Cancer | TERMINATED | NCT00358566 |
| Placebo | DRUG | Phase PHASE2 | Hypochondroplasia | RECRUITING | NCT07126262 |
| Lenalidomide 10 mg | DRUG | Phase PHASE3 | Myelodysplastic Syndromes | COMPLETED | NCT00179621 |
| Lenalidomide 5 mg | DRUG | Phase PHASE3 | Myelodysplastic Syndromes | COMPLETED | NCT00179621 |
| Extracorporeal Photopheresis | PROCEDURE | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00221026 |
| Methoxsalen +ECP | DRUG | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00221026 |
Total products: 463